Research graph
References from PDZ domain containing 1 sensitizes renal cancer cells to everolimus via inhibiting phosphatase and tensin homolog phosphorylation-mediated mTOR pathway activation. Local targets link to admitted publications; unresolved targets remain external evidence.
Epigenome aberrations: emerging driving factors of the clear cell renal cell carcinoma
10.3390/ijms18081774 · 2017 · External reference
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors
10.1016/j.eururo.2025.06.005 · 2025 · External reference
Global, regional, and national burden of kidney cancer and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projections to 2040
10.1186/s12885-025-13902-w · 2025 · External reference
Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy
10.1111/iju.12147 · 2013 · External reference
Recent Advances in nccRCC Classification and Therapeutic Approaches
10.3390/cells14221781 · 2025 · External reference
Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3/BCL-XL pathway
10.1016/j.canlet.2025.217514 · 2025 · External reference
Targeted therapy in metastatic renal carcinoma
10.1016/j.canlet.2013.09.038 · 2014 · External reference
Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors
10.1002/ijc.28023 · 2013 · External reference
Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions
2025 · External reference
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
10.1007/s00280-013-2339-y · 2014 · External reference
Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus
10.1111/cas.13169 · 2017 · External reference
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
10.1016/s1470-2045(15)00290-9 · 2015 · External reference
Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study
10.1111/iju.13776 · 2018 · External reference
ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma
10.1016/j.omtn.2019.01.001 · 2019 · External reference
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
10.1158/1535-7163.mct-17-1299 · 2018 · External reference
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor
10.3390/cancers11060830 · 2019 · External reference
PTEN suppresses tumorigenesis by directly dephosphorylating Akt
10.1038/s41392-021-00571-x · 2021 · External reference
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
10.1038/s41580-018-0015-0 · 2018 · External reference
Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN
2011 · External reference
Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma
10.1038/ncomms8353 · 2015 · External reference
Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN
10.1016/j.biopha.2018.08.127 · 2018 · External reference
OTUD1 stabilizes PTEN to inhibit the PI3K/AKT and TNF-alpha/NF-kappaB signaling pathways and sensitize ccRCC to TKIs
10.7150/ijbs.68980 · 2022 · External reference
Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
10.1093/annonc/mdi182 · 2005 · External reference
High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models
10.1371/journal.pone.0056185 · 2013 · External reference
Genomic rearrangements of PTEN in prostate cancer
10.3389/fonc.2013.00240 · 2013 · External reference
Phosphorylation and inactivation of PTEN at residues Ser380/Thr382/383 induced by Helicobacter pylori promotes gastric epithelial cell survival through PI3K/Akt pathway
10.18632/oncotarget.5577 · 2015 · External reference
Phosphorylation of the PTEN tail regulates protein stability and function
10.1128/mcb.20.14.5010-5018.2000 · 2000 · External reference
A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN
10.1073/pnas.0811212106 · 2009 · External reference
Loss of PDZK1 expression activates PI3K/AKT signaling via PTEN phosphorylation in gastric cancer
10.1016/j.canlet.2019.03.043 · 2019 · External reference
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240
10.1073/pnas.1211962109 · 2012 · External reference
Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma
10.1093/annonc/mdp600 · 2010 · External reference
Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma
10.1016/j.ebiom.2016.12.003 · 2017 · External reference
GSVA: gene set variation analysis for microarray and RNA-seq data
10.1186/1471-2105-14-7 · 2013 · External reference
The SR-BI partner PDZK1 facilitates hepatitis C virus entry
10.1371/journal.ppat.1001130 · 2010 · External reference
YTHDF3 phase separation regulates HSPA13-dependent clear cell renal cell carcinoma development and immune evasion
10.1111/cas.16228 · 2024 · External reference
Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation
10.1038/s41388-020-1297-1 · 2020 · External reference
PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation
10.1038/onc.2017.199 · 2017 · External reference
Accurate structure prediction of biomolecular interactions with AlphaFold 3
10.1038/s41586-024-07487-w · 2024 · External reference
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A
10.1186/1476-4598-13-152 · 2014 · External reference
Kinases, tails and more: regulation of PTEN function by phosphorylation
10.1016/j.ymeth.2014.10.015 · 2015 · External reference
Exosome-mediated delivery of the intrinsic C-terminus domain of PTEN protects it from proteasomal degradation and ablates tumorigenesis
10.1038/mt.2014.202 · 2015 · External reference
Direct identification of PTEN phosphorylation sites
10.1016/s0014-5793(02)03274-x · 2002 · External reference
PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis
10.1158/0008-5472.can-23-1730 · 2024 · External reference
The DRAP1/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer
10.1158/0008-5472.can-23-2781 · 2024 · External reference
Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations
10.1177/1756283x13496970 · 2013 · External reference
The structural basis of PTEN regulation by multi-site phosphorylation
10.1038/s41594-021-00668-5 · 2021 · External reference
The C-terminus of the transmembrane mucin MUC17 binds to the scaffold protein PDZK1 that stably localizes it to the enterocyte apical membrane in the small intestine
10.1042/bj20071068 · 2008 · External reference
Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383
2001 · External reference
Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane
10.1073/pnas.0510570103 · 2006 · External reference
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2
10.1073/pnas.97.8.4233 · 2000 · External reference
Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex
10.1074/jbc.c100556200 · 2001 · External reference
EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation
10.1007/s00726-012-1277-z · 2012 · External reference
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
10.1016/j.semcancer.2021.06.019 · 2022 · External reference
Mechanisms of resistance to mTOR inhibitors
10.1016/j.critrevonc.2020.102886 · 2020 · External reference
PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth
10.2119/molmed.2011.00001 · 2013 · External reference
Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma
10.1016/s0002-9440(10)63276-2 · 2004 · External reference
PDZK1 regulates breast cancer resistance protein in small intestine
10.1124/dmd.111.040295 · 2011 · External reference
PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway
10.1038/s41419-024-06502-2 · 2024 · External reference
PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway
10.1038/s41416-024-02725-4 · 2024 · External reference
Unresolved reference
2016 · External reference
Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells
10.2147/dddt.s160557 · 2018 · External reference
Methuosis inducer SGI-1027 cooperates with everolimus to promote apoptosis and pyroptosis by triggering lysosomal membrane permeability in renal cancer
2024 · External reference
